fbpx

molecules of the month

ASP2453

oral drug, covalent inhibitor of KRASG12C

effective in KRASG12C-mutated cancer models

SBDD utilizing KRAS proto-oncogene, GTPase

British Journal of Cancer

Astellas Pharma Inc.

Chemical structure of molecule ASP2453 Astellas KRASG12C covalent inhibitor
1 min read

3.      The Astellas KRASG12C covalent inhibitor, ASP2453, is an oral molecule with activity in preclinical mouse models of KRASG12C-mutated cancer at lower doses than sotorasib (AMG 510). Several KRAS inhibitors have been highlighted recently. ASP2453 possesses an interesting spirocyclic azetidine-containing acrylamide warhead, and the authors note that ASP2453 is likely more reactive than piperazine-bearing AMG 510. ASP2453 does not appear to have entered clinical development yet.


request a trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.

Interested in learning more? Submit this form to request a trial.


already a member? log in: